This document provides an overview of Inovio Pharmaceuticals' DNA vaccine technology and development programs. Key points: - Inovio is developing DNA vaccines that use electroporation to deliver DNA plasmids encoding disease antigens to cells, stimulating antibody and T-cell immune responses. - Their lead program is a therapeutic HPV vaccine (VGX-3100) in Phase II testing for cervical dysplasia. Efficacy data is expected in mid-2014. - Inovio's technology is aimed at revolutionizing vaccines by producing ones that are synthetic rather than weakened viruses, can target multiple strains, and stimulate both preventive and therapeutic immune responses. - The company has a pipeline